AMNEAL PHARMACEUTICALS INC (AMRX)
US03168L1052 - Common Stock
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Amneal to Report First Quarter 2024 Results on May 3, 2024
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!
Amneal Pharmaceuticals Non-GAAP EPS of $0.14 beats by $0.05, revenue of $617M misses by $17.86M (NASDAQ:AMRX)
Amneal Pharmaceuticals reports Q4 earnings, beating earnings per share estimates but missing revenue expectations.
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
Amneal to Participate at Upcoming Investor Conference
Amneal resubmits FDA application for Parkinson's disease drug (NASDAQ:AMRX)
Amneal Pharmaceuticals (AMRX) has resubmitted its application to the FDA for its Parkinson's disease drug IPX203 after receiving a Complete Response Letter. Read more here.
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
BRIDGEWATER, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has...
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
Amneal Pharma stock gains after licensing pact (NASDAQ:AMRX)
Knight Therapeutics(KHTRF) partners with Amneal Pharma (AMRX) for exclusive rights to Parkinson's disease drug IPX203 in Canada and Latin America. Read more here.
Commit To Purchase Amneal Pharmaceuticals At $5, Earn 23.7% Annualized Using Options
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
INVESTIGATION ALERT: Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Encourages Long-Term Investors to Contact the Firm
/PRNewswire/ -- Kaskela Law LLC announces that it is investigating Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal") on behalf of the Company's shareholders....
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
Noteworthy Wednesday Option Activity: AMRX, FLGT, DXCM
Amneal announces move to Nasdaq (NYSE:AMRX)
Amneal Pharmaceuticals will move its stock exchange listing to Nasdaq from NYSE, joining Nasdaq Composite Index and Nasdaq Biotechnology Index.
Amneal Announces Move to Nasdaq
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
Amneal Reports Third Quarter 2023 Financial Results
Amneal to Participate at Upcoming Investor Conferences
Amneal Pharmaceuticals raises its FY outlook (NYSE:AMRX)
Amneal Pharmaceuticals raises full year outlook amid robust Q3 growth, expecting increased adjusted EPS and revenue.
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
Amneal to reorganize and simplify corporate structure (AMRX)
Amneal Pharmaceuticals (AMRX) said it is reorganizing and simplifying its corporate structure, which includes eliminating its umbrella partnership-C-corporation structure.
Commit To Purchase Amneal Pharmaceuticals At $2.50, Earn 9.7% Annualized Using Options